Stockscreener 앱 받기
13.61
3.50%
0.46
시간 외 거래:
13.49
-0.12
-0.88%
전일 마감가:
$13.15
열려 있는:
$13.2
하루 거래량:
2.46M
Relative Volume:
0.52
시가총액:
$867.02M
수익:
-
순이익/손실:
$-145.21M
주가수익비율:
-5.9174
EPS:
-2.3
순현금흐름:
$-140.12M
1주 성능:
+1.57%
1개월 성능:
+42.96%
6개월 성능:
-65.04%
1년 성능:
-74.88%
1일 변동 폭
$13.04
$13.62
1주일 범위
$12.43
$13.99
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
MLTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
13.61 | 931.64M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
MLTX Class Action Reminder – Robbins LLP Reminds MoonLake - GlobeNewswire
DEADLINE ALERT for ATYR, MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Urges Investors of aTyr, Marex, - GlobeNewswire
MoonLake Immunotherapeutics’ (MLTX) Reported Phase 3 Trial - GlobeNewswire
Investors in MoonLake Immunotherapeutics Should Contact The - GlobeNewswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
2025-11-24 | Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action | NDAQ:MLTX | Press Release - Stockhouse
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MoonLake Immunotherapeutics Sued for Securities Law Violations - GuruFocus
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
2025-11-23 | Investors in MoonLake Immunotherapeutics (MLTX): Protect Your RightsContact Levi & Korsinsky Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MLTX INVESTOR REMINDER: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action Lawsuit - MarketScreener
MLTX COURT ALERT: MoonLake Immunotherapeutics Investors that Lost Money May have been Affected by Fraud -- Contact BFA Law by December 15 - GlobeNewswire
HC Wainwright Lowers MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $26.00 - Defense World
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - Morningstar
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionMLTX - MarketScreener
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - PR Newswire
Moonlake Immunotherapeutics stock price target lowered to $26 at H.C. Wainwright - Investing.com India
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - Nasdaq
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Burned by MoonLake Immunotherapeutics? Contact Levi & Korsinsky to SueWallSt And Fight Back - ACCESS Newswire
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join - GlobeNewswire
MLTX INVESTORS: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses to Contact the Firm Before the Imminent December 15 Securities Class Action Deadline - MarketScreener
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - FinancialContent
MLTX LAWSUIT ALERT: The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
MLTX LEGAL REMINDER: MoonLake Immunotherapeutics Faces Securities Allegations over Drug Trial Results -- Investors Alerted to Contact BFA Law before December 15 - ACCESS Newswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake - GlobeNewswire
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
The Gross Law Firm Notifies MoonLake Immunotherapeutics - GlobeNewswire
MLTX LAWSUIT: MoonLake Immunotherapeutics Investors are Notified to Contact BFA Law about the Filed Securities Fraud Class Action and Important December 15 Deadline - Newsfile
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - The Globe and Mail
Holdings of MoonLake Immunotherapeutics (MLTX) are aligned with the stars - Setenews
MLTX CLASS NOTICE: BFA Law Alerts MoonLake Immunotherapeutics Investors of the Pending Securities Fraud Class Action and Upcoming December 15 Deadline - Newsfile
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action - GuruFocus
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - PR Newswire
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out - Yahoo Finance
Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones - news.stocktradersdaily.com
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Over Securities ViolationsContact Levi & Korsinsky Today - Newsfile
MLTX DEADLINE REMINDER: MoonLake Immunotherapeutics 90% Stock Drop Triggers Securities Fraud Class ActionInvestors Urged to Contact BFA Law by December 15 - ACCESS Newswire
MLTX MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - MarketScreener
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - GlobeNewswire
MLTX DEADLINE REMINDER: Berger Montague Reminds MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Important Class Action Lawsuit Deadline - Eastern Progress
MoonLake Immunotherapeutics Stock: Ignore The Panic, Catch The Upside (NASDAQ:MLTX) - Seeking Alpha
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Chen Bihua | Former 10% Owner |
Sep 29 '25 |
Sale |
7.21 |
6,494,151 |
46,827,628 |
2,000,000 |
| Chen Bihua | Former 10% Owner |
Sep 30 '25 |
Sale |
6.96 |
5,827 |
40,556 |
1,994,173 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Option Exercise |
0.00 |
23,500 |
0 |
23,500 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
0.53%
1.88%
자본화:
|
볼륨(24시간):